Please assess the completion status of the following clinical trial:

Trial Title: Filtered Trial for Amlodipine Non-responder

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Essential hypertensive patients satisfying all of the following criteria;~2. Male or Female~3. Age \> 20 years~4. Outpatient~5. Patients who are able to stop current anti-hypertensive therapy at Visit 1 if taking any anti-hypertensive medications~6. Patients with an ability to provide written informed consent in accordance with the related laws and guidelines such as Good Clinical Practice (GCP) and the Pharmaceutical Affairs Law.~Exclusion Criteria:~1. Taking four or more anti-hypertensive medications~2. Secondary hypertension~3. Mean seated diastolic blood pressure (DBP) \> 114 mmHg and/or mean seated systolic blood pressure (SBP) \> 200 mmHg at Visit 1, 2, 3, or 4, or mean seated DBP \< 90 mmHg at Visit 3.~4. Sustained ventricular tachycardia or other clinically relevant cardiac arrhythmias~5. Congestive heart failure patients with the New York Heart Association (NYHA) functional class III-IV~6. History of myocardial infarction or cardiac surgery within last 6 months~7. History of coronary artery bypass graft or percutaneous coronary intervention (PCI) within last 3 months~8. History of unstable angina within last 3 months~9. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve~10. History of stroke or transient ischemic attack within last 6 months~11. History of sudden exacerbation of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors, or patients with post-renal transplant or post-nephrectomy~12. Experienced characteristic symptoms of angioedema during treatment with ARBs or ACE inhibitors~13. Known hypersensitivity to any component of the investigational drug , or a known hypersensitivity to dihydropyridine -derived drugs~14. Hepatic and/or renal dysfunction~15. Diagnosed biliary atresia or cholestasis~16. Hyperkalemia~17. Dehydration~18. Sodium deficiency~19. Chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs (NSAIDs)~20. Patients who cannot change to the restricted administration and dosage during study period~21. Pre-menopausal women who meet any one of the following 1 - 3:~    * Pregnant or possibly pregnant (1)~   * Nursing (2)~   * Desire to become pregnant during study period (3)~22. Drug or alcohol dependency~23. Complication of malignant tumour or a disease requiring immunosuppressants~24. Compliance of \< 80% or \> 120% during the run-in period~25. Receiving any investigational therapy within 3 months~26. Judged to be inappropriate by the investigator or the sub-investigator

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).